Neurocrine Biosciences Inc
NASDAQ:NBIX

Watchlist Manager
Neurocrine Biosciences Inc Logo
Neurocrine Biosciences Inc
NASDAQ:NBIX
Watchlist
Price: 134.63 USD -0.58%
Market Cap: 13.6B USD
Have any thoughts about
Neurocrine Biosciences Inc?
Write Note

Neurocrine Biosciences Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Neurocrine Biosciences Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Neurocrine Biosciences Inc
NASDAQ:NBIX
Revenue
$2.2B
CAGR 3-Years
28%
CAGR 5-Years
27%
CAGR 10-Years
124%
Abbvie Inc
NYSE:ABBV
Revenue
$55.5B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$28.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Revenue
$32.5B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.6B
CAGR 3-Years
14%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.8B
CAGR 3-Years
1%
CAGR 5-Years
16%
CAGR 10-Years
18%
No Stocks Found

Neurocrine Biosciences Inc
Revenue Breakdown

Breakdown by Geography
Neurocrine Biosciences Inc

Not Available

Breakdown by Segments
Neurocrine Biosciences Inc

Total Revenue: 1.9B USD
100%
Net Product Sales: 1.9B USD
98.6%
Collaboration Revenue: 26.5m USD
1.4%

Neurocrine Biosciences Inc
Glance View

Market Cap
13.6B USD
Industry
Biotechnology
Economic Moat
Wide

Neurocrine Biosciences Inc. is a biopharmaceutical company that has carved out a notable niche in the neurosciences landscape. Founded in 1992, this San Diego-based firm has dedicated itself to developing treatments for neurological and endocrine-related disorders. With a strong focus on conditions such as Parkinson's disease, tardive dyskinesia, and epilepsy, Neurocrine leverages its expertise in neuroscience to bring innovative therapies to those who need them most. The company’s flagship product, Ingrezza, primarily used to treat tardive dyskinesia, reflects their commitment to addressing complex, unmet medical needs. Successfully obtaining FDA approval not only boosted patient outcomes but also established Neurocrine as a leader in a specialized segment of the pharmaceutical industry. Neurocrine’s financial model thrives on the commercialization of its proprietary medications. By partnering strategically with other pharmaceutical giants, such as AbbVie, they can broaden their market reach and accelerate development of new treatments. The company generates revenue predominantly through product sales, royalties, and milestone payments associated with its collaborations. Their pipeline remains robust, focusing on both expanding indications for existing drugs and pioneering new treatments. Each new approval or advancement in clinical trials further solidifies their market position and offers potential for increased financial returns. Thus, Neurocrine Biosciences operates at the intersection of science and business, continuously pushing the boundaries of neurological treatment while maintaining a steady growth trajectory.

NBIX Intrinsic Value
139 USD
Undervaluation 3%
Intrinsic Value
Price

See Also

What is Neurocrine Biosciences Inc's Revenue?
Revenue
2.2B USD

Based on the financial report for Sep 30, 2024, Neurocrine Biosciences Inc's Revenue amounts to 2.2B USD.

What is Neurocrine Biosciences Inc's Revenue growth rate?
Revenue CAGR 10Y
124%

Over the last year, the Revenue growth was 26%. The average annual Revenue growth rates for Neurocrine Biosciences Inc have been 28% over the past three years , 27% over the past five years , and 124% over the past ten years .

Back to Top